MoonLake Immunotherapeutics
MLTX | NASDAQ
$12.79
+$0.24 (+1.91%)
Sep 22, 2026, 1:46 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -3.73 | -28.65 | -82.73 | -4.77 | -6.82 | -1.86K |
PEG Ratio | -0.04 | -0.18 | 1.24 | -0.09 | 0 | n/a |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 2.79 | 7.62 | 5.98 | 6.30 | -31.36 | 1.50 |
P/FCF Ratio | -4.33 | -29.07 | -68.89 | -5.51 | -10.37 | -531.53 |
P/OCF Ratio | -4.33 | -29.20 | -69.35 | -5.52 | -10.38 | -531.53 |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0.25 | 0.01 | 0.01 | 0.01 | -1.29 | 0 |
Quick Ratio | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 | 12.93 |
Current Ratio | 9.27 | 21.11 | 51.59 | 9.98 | 0.46 | 12.93 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | -33.78 | n/a | n/a | n/a | n/a | n/a |
Return on Equity | -74.66% | -26.62% | -7.26% | -102.20% | 460.66% | -0.08% |
Return on Assets | -53.56% | -24.89% | -6.84% | -65.03% | -554.03% | -0.08% |
Return on Invested Capital | -64.40% | -31.32% | -10.45% | -93.84% | -1.49K% | -0.09% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove MLTX